Abstract | BACKGROUND: Although DNA-directed alkylating agents and related compounds have been a mainstay in chemotherapeutic protocols due to their ability to readily interfere with the rapid mitotic progression of malignant cells, their clinical utility is limited by DNA repair mechanisms and immunosuppression. However, the same destructive nature of alkylation can be reciprocated at the cell surface using novel plasma membrane alkylating agents. RESULTS: CONCLUSION: Despite these compelling data, preliminary clinical trials for plasma membrane-directed agents have yet to be considered. Therefore, this review is intended for academics and clinicians to postulate a novel approach of chemotherapy; altering critical malignant cell signaling at the plasma membrane surface through alkylation, thereby inducing irreversible changes to functions needed for cell survival.
|
Authors | Matthew Trendowski, Thomas P Fondy |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 33
Issue 4
Pg. 992-1001
(Aug 2015)
ISSN: 1573-0646 [Electronic] United States |
PMID | 26095786
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Alkylating
|
Topics |
- Alkylation
- Animals
- Antineoplastic Agents, Alkylating
(pharmacology)
- Cell Membrane
(metabolism)
- Neoplasms
(drug therapy, metabolism)
|